Management Team

Anthony J. Cataldo

Chairman, Chief Executive Officer & President

Mr. Cataldo founded GT Biopharma Inc. upon joining the Board of Directors and subsequently Chairman and CEO in in July of 2014, where he changed the Company's profile with the inclusion of oncology assets. From February 2011 to June 2013 Mr. Cataldo served as Founder and Chairman/CEO of Genesis Biopharma, Inc., now known as Iovance Biotherapeutics, Inc., (IOVA). Mr. Cataldo created the highly successful IOVA/Genesis with the inclusion of assets acquired from the National Cancer Institute for the treatment of stage four melanoma. Mr. Cataldo has extensive experience in the biotechnology sector having served as Chairman/CEO of several biotech companies including: Calypte Biomedical Corporation, and Senetek, PLC.

Jeffrey S. Miller, M.D.

Consulting Chief Medical Officer

Jeffrey S. Miller, MD, received a Bachelor of Science degree from Northwestern University in Evanston, Illinois and received his MD from Northwestern University School of Medicine. He completed an internship and residency in Internal Medicine at the University of Iowa in Iowa City. After completing a post-doctoral fellowship in Hematology, Oncology and Transplantation at the University of Minnesota, he joined the faculty in 1991. Dr. Miller is currently a Professor of Medicine at the University of Minnesota. He is the Deputy Director of the University of Minnesota Masonic Comprehensive Cancer Center. He has more than 20 years of experience studying the biology of NK cells and other immune effector cells and their use in clinical immunotherapy with over 170 peer-reviewed publications. He is a member of numerous societies such as the American Society of Hematology, the American Association of Immunologists, a member of the American Society of Clinical Investigation since 1999. He serves on the editorial board for Blood and is a reviewer for a number of journals and NIH grants.

Steven Weldon

Chief Financial Officer & Director

Mr. Weldon has extensive experience with the Company having served on our Board of Directors from September 2014 through October 2018.  He also served as Chief Financial Officer from November 2014 through October 2018. Mr. Weldon has over 16 years of financial and accounting experience. Mr. Weldon's financial background includes experience in managerial, private accounting and planning. He has served on the board of several publicly traded companies as both, chief executive officer and chief financial officer. Mr. Weldon was appointed as chief financial officer and as a member of the board of directors of GB Sciences, Inc. (OTCMKTS:GBLX) in September 2005 and served in both positions until November 2014. Mr. Weldon also served as chief executive officer of GB Sciences from December 2009, through May 2011, and from April 2012, through March 2014. For several years, he taught accounting and tax courses to undergrad students at Florida Southern College. He received his bachelor of science degree and his Master's in Business Administration from Florida Southern College and is a licensed Certified Public Accountant in the State of Florida.

Martin Schroeder

Consulting Chief Technology Officer

Mr. Schroeder was appointed consulting CTO of GT Biosciences, Inc. in April of 2019. Mr. Schroeder has been Executive Vice President and Managing Director of the Emmes Group, Inc., a strategic advisory firm. Prior to joining the Emmes Group, Mr. Schroeder held a number of industry management and executive positions, including Chairman, President and Chief Executive Officer of AMS, Inc., a venture capital-backed molecular genomics company. From August 2007 through April 2008, Mr. Schroeder was a member of the Board of Directors of Global Clean Energy Holdings, Inc., a public company engaged in the development of nonfood-based bio-fuel feedstock. Mr. Schroeder also played key roles in the founding of Intercept Pharmaceuticals, a public biotech company focused on the treatment of patients with progressive non-viral liver diseases, and the founding of Iovance Biotherapeutics, a public company developing cell therapy products. Mr. Schroeder was also a Visiting Scientist at the U.S. Department of Agriculture following completion of his graduate studies in biochemistry. 

Mr. Schroeder holds a Bachelor of Science degree in Biochemistry from the University of California Los Angeles, and a Master of Science degree in Biochemistry from California State University, Long Beach.